+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bioresorbable Stents - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 125 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4804736

Global Bioresorbable Stents Market to Reach $692 Million by 2027

Growth in the global market is set to be fueled by increasing prevalence of cardiovascular diseases such as peripheral artery and coronary artery diseases, increasing elderly population, and fast increasing obese population. Additional growth factors include an increase in number of PCI procedures performed each year, more patients favoring minimally invasive therapies, higher adoption of these stents by patients and physicians alike, and greater number of clinical trials evaluating the use of bioabsorbable stents. The popularity of bioabsorbable stents is influenced by the elimination of the need to perform stent-in-stent procedures, elimination of the requirement for dual anti-platelet therapies, higher degree of effectiveness in treating coronary artery diseases, and the possibility of achieving accurate stent placement as well as cost-effectiveness of the treatment.

In the changed post COVID-19 business landscape, global market for Bioresorbable Stents estimated at US$317 Million in the year 2020, is projected to reach a revised size of US$692 Million by 2027, growing at a CAGR of 11.8% over the analysis period 2020-2027. Polymer-Based, one of the segments analyzed in the report, is projected to record more than 10% CAGR and reach more than US$450 Million by the end of the analysis period.

Select Competitors (Total 25 Featured) -

  • Abbott Laboratories
  • Arterius Limited
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Elixir Medical Corp.
  • Kyoto Medical Planning Co., Ltd.
  • LEPU MEDICAL TECHNOLOGY CO., LTD.
  • Meril Life Sciences Pvt. Ltd.
  • REVA Medical, Inc.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to a digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2022 (E)
  • Coronary Artery Disease (CAD) - A Perspective
  • Causes and Symptoms
  • Treatment Options for Coronary Artery Disease
  • Percutaneous Coronary Intervention (PCI)
  • Coronary Stenting
  • Types of Coronary Stents
  • Bare Metal Stents (BMS)
  • Drug Eluting Stents (DES)
  • Bioresorbable Scaffolds
  • Design and Composition of Bioresorbable Scaffolds
  • Different Types of Bioresorbable Scaffolds
  • Metallic Bioresorbable Scaffolds
  • Polymer Bioresorbable Scaffolds
  • Degradation Period of Select Bioabsorbable Materials
  • Challenges
  • Clinical Characteristics of Various Coronary Stents
  • Other Treatment Options for Coronary Heart Disease
  • Coronary Artery Bypass Grafting (CABG)
  • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
  • TransMyocardial Laser Revascularization (TMR)
  • Peripheral Arterial Disease: Understanding the Stealthy Peril
  • Treatment for PAD
  • Stenting- A Treatment Option for PAD
  • BioResorbable Stents - A Prelude
  • Bioresorbable Vascular Scaffolds: Advantages and Challenges
  • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
  • Abbott Stops Sales of the Once Promising ‘Absorb' Bioresorbable Stents due to Adverse Events
  • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
  • Impact of Covid-19 and a Looming Global Recession
  • 2020 Marked as a Year of Disruption & Transformation
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • Impact of COVID - 19 on Coronary Stents Market
  • Impact on Supply Chain
  • Impact of COVID-19 Outbreak on Elective Surgeries
  • Global Bioresorbable Stents Market Buckles under COVID-19 Strain
  • GLOBAL MARKET OVERVIEW
  • Global Bioresorbable Stents Set to Witness Growth in Future
  • Europe Dominates, Asia-Pacific Exhibits Fastest Growth
  • CAD Constitutes the Leading Application
  • Metallic Vs. Polymer-based Stents
  • Bioabsorbable Metallic Stents
  • Bioabsorbable Polymer Stents
  • Disappointing Results by Absorb to Increase Focus on Metallic Stents
  • Availability of Alternative Treatments - Hindrance to Market Growth
  • Market Challenges
  • MARKET OUTLOOK
  • Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
  • The Future of BRS Technology
  • COMPETITION
  • Select Approved Bioresorbable Scaffolds
  • Select Bioresorbable Stents in Pipeline
  • Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
  • Recent Market Activity
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Polymeric Resorbable Scaffolds Hold a Major Market Share
  • The Absorb BRS program
  • Desaminotyrosine Polycarbonate-based BRS
  • The FANTOM program
  • Magnesium-based BRS
  • The Magmaris program
  • Iron-based BRS
  • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
  • Global Annual Medical Cost of CVD in the United States: 2015-2030
  • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Rising Middle Class Population Aids Growth
  • Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
  • Rising Healthcare Expenditure: Opportunities in Store
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
  • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
  • Diabetics at Higher Risk of Heart Diseases
  • Table 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
  • The Hypertension-Cholesterol Link to Drive Demand
  • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
  • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
  • Metal Stents Vis-à-Vis Other Stents
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
  • Table 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
III. MARKET ANALYSIS
EUROPE
  • Table 15: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 16: Europe 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2021 & 2027
  • Table 17: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 18: Europe 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2021 & 2027
  • Table 19: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: Europe 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2021 & 2027
ASIA-PACIFIC
  • Table 21: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 22: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2021 & 2027
  • Table 23: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 24: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2021 & 2027
  • Table 25: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2021 & 2027
REST OF WORLD
  • Table 27: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: Rest of World 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2021 & 2027
  • Table 29: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 30: Rest of World 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2021 & 2027
  • Table 31: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Rest of World 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2021 & 2027
IV. COMPETITION
  • Total Companies Profiled: 25

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Arterius Limited
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Elixir Medical Corp.
  • Kyoto Medical Planning Co., Ltd.
  • LEPU MEDICAL TECHNOLOGY CO., LTD.
  • Meril Life Sciences Pvt. Ltd.
  • REVA Medical, Inc.